KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Research & Development (2017 - 2025)

Historic Research & Development for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Q3 2025 value amounting to $409.5 million.

  • Biomarin Pharmaceutical's Research & Development rose 12145.8% to $409.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $903.0 million, marking a year-over-year increase of 1578.37%. This contributed to the annual value of $747.2 million for FY2024, which is 5.5% up from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported Research & Development of $409.5 million as of Q3 2025, which was up 12145.8% from $161.3 million recorded in Q2 2025.
  • Biomarin Pharmaceutical's Research & Development's 5-year high stood at $409.5 million during Q3 2025, with a 5-year trough of $148.7 million in Q1 2021.
  • In the last 5 years, Biomarin Pharmaceutical's Research & Development had a median value of $171.8 million in 2023 and averaged $184.3 million.
  • Data for Biomarin Pharmaceutical's Research & Development shows a peak YoY increase of 12145.8% (in 2025) and a maximum YoY decrease of 2256.53% (in 2025) over the last 5 years.
  • Over the past 5 years, Biomarin Pharmaceutical's Research & Development (Quarter) stood at $161.1 million in 2021, then grew by 7.24% to $172.8 million in 2022, then increased by 19.39% to $206.2 million in 2023, then decreased by 15.87% to $173.5 million in 2024, then soared by 136.0% to $409.5 million in 2025.
  • Its Research & Development stands at $409.5 million for Q3 2025, versus $161.3 million for Q2 2025 and $158.7 million for Q1 2025.